BioNTech, Pfizer partner to develop mRNA therapies for flu

BioNTech AG (Mainz, Germany) partnered with Pfizer Inc. (NYSE:PFE) to develop mRNA-based influenza vaccines, marking the biotech's first step toward building an R&D presence in

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE